EP0593536A1 - DERIVES DIBENZ b,e]AZEPINES ET MEDICAMENTS LES CONTENANT - Google Patents

DERIVES DIBENZ b,e]AZEPINES ET MEDICAMENTS LES CONTENANT

Info

Publication number
EP0593536A1
EP0593536A1 EP92913494A EP92913494A EP0593536A1 EP 0593536 A1 EP0593536 A1 EP 0593536A1 EP 92913494 A EP92913494 A EP 92913494A EP 92913494 A EP92913494 A EP 92913494A EP 0593536 A1 EP0593536 A1 EP 0593536A1
Authority
EP
European Patent Office
Prior art keywords
formula
dibenz
compound
dihydro
given above
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92913494A
Other languages
German (de)
English (en)
Inventor
Walter-Gunar Friebe
Herbert Leinert
Alfred Mertens
Wolfgang Schäfer
Harald Zilch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH, Boehringer Mannheim GmbH filed Critical Roche Diagnostics GmbH
Publication of EP0593536A1 publication Critical patent/EP0593536A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to
  • Dibenz [b, e] azepine derivatives processes for their preparation and medicaments containing these compounds.
  • the invention relates to dibenz [b, e] azepine derivatives of the general formula I
  • A is a methylene, carbonyl, thiocarbonyl, carbimino, N-hydroxycarbimino or sulfonyl group
  • X is a valence bond or an oxygen or sulfur atom, a sulfinyl or sulfonyl group, a CH2S group or an NH group,
  • n is an integer from 1 to 3 and
  • R 1 to R 3 which can be the same or different independently of one another, are each a hydrogen atom, a straight-chain or branched, saturated or unsaturated aliphatic radical with 1-6 C-ato or C -C 6 -alkoxy, Cx-Cg-alkylmercapto, C 1 -Cs-alkylsulfinyl, Ci-Cg-alkylsulfonyl, A ino, C 1 -Cg-alkylamino, di- Ci-Cs-alkylamino, sulfonamido, C ⁇ -Cg alkoxycarbonyl, carboxy, halogen, hydroxy, nitro, cyano, azido, phenyl or benzyloxy and
  • R 4 is hydrogen or a straight-chain or branched, saturated or unsaturated aliphatic radical having 1-6 C atoms
  • the object of the present invention was to provide new dibenz [b, e] azepine derivatives. These compounds are used in particular for the production of medicaments.
  • the compounds of the present invention have valuable pharmacological properties. They are particularly suitable for the therapy and prophylaxis of infections caused by DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, papilloma viruses, the varicella zoster virus or Epstein-Barr-Vl üs or RNA viruses such as toga viruses or in particular retroviruses such as the oncoviruses HTLV-I and II, as well as the lentiviruses Visna and the human immunodeficiency virus HIV-1 and -2.
  • DNA viruses such as e.g. the herpes simplex virus, the cytomegalovirus, papilloma viruses, the varicella zoster virus or Epstein-Barr-Vl üs or RNA viruses such as toga viruses or in particular retroviruses such as the oncoviruses HTLV-I and II, as well as the lentiviruses Visna and the human immunodefic
  • the compounds of the formula I appear to be particularly suitable for the treatment of the clinical manifestations of retroviral HIV infection in humans, such as persistent, generalized lymphadenopathy (PGL), the advanced stage of the AIDS-related complex (ARC) and the clinical picture of AIDS.
  • PDL generalized lymphadenopathy
  • ARC advanced stage of the AIDS-related complex
  • the compounds of general formula I according to the invention have a pronounced antiviral effect and are particularly suitable for the treatment of viral or retro-viral infections.
  • Viral infections in mammals, especially humans, are common.
  • Che otherapeutics which cause causally or symptomatically to interfere with the viral or retroviral-related illness with evidently substantial success.
  • AIDS Acquired Immune Deficiency Syndro
  • ARC AIDS-related complex
  • CMV cytomegalovirus
  • influenza influenza and other viral infections to heal or to chemically influence the symptoms favorably.
  • 3 '-azido-3' deoxythymidine (AZT) known as Zidovudine or Retrovir R
  • Zidovudine or Retrovir R 3 '-azido-3' deoxythymidine
  • AZT 3 '-azido-3' deoxythymidine
  • Zidovudine or Retrovir R 3 '-azido-3' deoxythymidine
  • Zidovudine or Retrovir R 3 '-azido-3' deoxythymidine
  • AZT 3 '-azido-3' deoxythymidine
  • Zidovudine or Retrovir R 3 '-azido-3' deoxythymidine
  • AZT 3 '-azido-3' deoxythy
  • the mentioned compounds are advantageously used prophylactically or therapeutically in the treatment of diseases in which a retroviral infection is of pathophysiological, symptomatic or clinical relevance.
  • the separation of the race ate into the enantiomers can be carried out analytically, semi-preparatively and preparatively chromatographically on suitable optically active phases with common eluents.
  • Suitable optically active phases are, for example, optically active polyacrylamides or polyethacrylamides, some also on silica gel (e.g. ChiraSpher (R) from Merck, Chiralpak (R) OT / OP from Baker), cellulose esters / carbamates (e.g. Chiracel (R ) OB / OY from Baker / Daicel), phases based on cyclodextrin or crown ether (for example Crownpak (R) from Daicel) or microcrystalline cellulose triacetate (Merck).
  • silica gel e.g. ChiraSpher (R) from Merck, Chiralpak (R) OT / OP from Baker
  • cellulose esters / carbamates e.g. Chiracel (R ) OB / OY from Baker / Daicel
  • phases based on cyclodextrin or crown ether for example Crownpak (R) from Daicel
  • Merck microcrystalline cellulose tria
  • A denotes in particular a carbonyl, methylene or thiocarbonyl group, the carbonyl group being preferred.
  • X represents in particular an oxygen or sulfur atom or a sulfinyl or sulfonyl group.
  • n is preferably the number 1 or 2.
  • R 1 to R 3 are hydrogen, C] _- C3-alkyl, C2-C4-alkenyl, C2-C -alkynyl, C ⁇ ⁇ C3-alkoxy, C_-C 3 -alkylmercapto, C ⁇ ⁇ C 3 -alkylamino , C ] _-C 3 alkoxycarbonyl, amino, halogen, hydroxy, cyano and azido preferred.
  • the ring system can be substituted in the 7-, 8-, 9- or 10-position by R 1 , the 8- and 9-position being preferred.
  • R 1 represents a halogen atom or a Ci-Cg-alkyl group.
  • R 2 and R 3 can be in the 1-, 2-, 3- or 4- position of the ring system, the 3- and 4-position are preferred.
  • R 2 represents a hydrogen atom and R 3 represents a hydrogen or halogen atom, a Ci-Cg-alkyl or Ci-Cg-alkoxy group.
  • R 3 is in particular a chlorine atom, or a methyl or methoxy group.
  • radical R 4 hydrogen, C 1 -C 3 -alkyl, C 2 -C 4 -alkenyl and C 2 -C 4 -alkynyl are preferred.
  • R 1 to R 3 independently of one another, hydrogen, methyl, ethyl, isopropyl, allyl, methoxy, ethoxy, methyl ercapto, ethyl mercapto, methylamino, methoxycarbonyl, ethoxycarbonyl, amino, azido, cyano, hydroxy and halogen, with chlorine and bromine are preferred for halogen.
  • R 4 hydrogen, methyl, ethyl, isopropyl and allyl are particularly preferred.
  • the aliphatic radical in the definition of R 1 -R 4 can be straight-chain or branched, saturated or unsaturated and contain a total of up to six carbon atoms.
  • Ci-Cg-alkyl groups are possible as saturated residues, such as. B. methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl or t-butyl.
  • Unsaturated radicals are in particular C2-Cg-alkenyl and C2-C 6 -alkynyl groups, which can also be branched, such as. As allyl, vinyl, 2-butenyl or propargyl.
  • the medicaments containing at least one compound of the formula I for the treatment of viral infections can be administered enterally or parenterally in liquid or solid form.
  • the usual forms of application come into question, such as tablets, capsules, dragees, syrups, solutions or suspensions.
  • Water is preferably used as the injection medium, which contains the additives customary for injection solutions, such as stabilizing agents, solubilizers and buffers.
  • additives are tartrate and Citrate buffer, ethanol, complexing agents such as ethylene diamine tetraacetic acid and its non-toxic salts, high molecular weight polymers such as liquid polyethylene oxide for viscosity regulation.
  • Liquid carriers for injection solutions must be sterile and are preferably filled into ampoules.
  • Solid carriers are, for example, starch, lactose, mannitol, methyl cellulose, talc, highly disperse silicas, higher molecular fatty acids, such as stearic acid, gelatin, agar-agar, calcium phosphate, magnesium stearate, animal and vegetable fats, solid high-molecular polymers, such as polyethylene glycols, etc.
  • suitable for applications can, if desired, contain flavorings or sweeteners.
  • Pharmacologically acceptable salts are the acid addition salts with inorganic or organic acids, such as. B. halogen acids (HC1, HBr, etc.), sulfuric acid, phosphoric acid, tartaric acid, succinic acid, oxalic acid, acetic acid.
  • B. halogen acids HC1, HBr, etc.
  • sulfuric acid phosphoric acid
  • tartaric acid tartaric acid
  • succinic acid oxalic acid
  • acetic acid acetic acid
  • the dosage can depend on various factors, such as the mode of application, species, age or individual condition.
  • the compounds according to the invention are usually applied in amounts of 0.1-100 mg, preferably 0.2-80 mg per day and per kg of body weight. It is preferred to distribute the daily dose over 2-5 applications, 1-2 applications with an active ingredient content of 0.5-500 mg being administered for each application.
  • the tablets can also be delayed, which reduces the number of applications per day to 1-3.
  • the ⁇ content of active substance of the retarded tablets can be 2 - mg 1000th
  • the active ingredient can also be given by continuous infusion, the amounts of 5-1000 mg per day being normally sufficient.
  • n has the meaning given above and Y 'and Y ", which are the same or different, have the meaning of Y,
  • A, X, n and R 1 to R 4 have the meaning given above and Z represents a reactive radical, cyclizes or
  • Racemates can be separated into the antipodes, for example, by chromatography on suitable optically active phases such as cellulose triacetate.
  • reactive residues X, Y, Y 1 and Y ".
  • the groups HY, HY 1 and HY" are advantageously eliminated in a solvent in the presence of a base such as for example an alkali alcoholate in the corresponding alcohol, potassium carbonate in acetone or butanone, sodium hydride in toluene or dimethylformamide.
  • a base such as for example an alkali alcoholate in the corresponding alcohol, potassium carbonate in acetone or butanone, sodium hydride in toluene or dimethylformamide.
  • reactive radicals Z can also be lower alkoxy groups, optionally substituted phenoxy groups or the azide radical.
  • the reduction of a carbonyl group to a CH2 group is advantageously carried out using complex metal hydrides such as lithium aluminum hydride or sodium borohydride or using catalytically excited hydrogen.
  • the test system contains the purified RT from HIV-1, which was expressed by genetic engineering methods in E. coli, as well as the components of the initiation complex, such as the in vitro transcripts of the HIV-LTR with the neighboring primer binding site as a template and one for Primer binding site complementary 18mer oligonucleotide as a primer.
  • the [ 3 H] -thymidine-5'-triphosphate incorporation was measured by counting in the ß-counter.
  • the table below shows the ICsoth for the compounds examined. This value corresponds to the concentration of the test substance which causes an inhibition of the reverse transcriptase activity by 50%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention a pour objet des dérivés dibenz[b,e]azépines de formule (I), dans laquelle A désigne un groupe méthylène, carbonyle, thiocarbonyle, carbimino, N-hydroxycarbimino ou sulfonyle, X est une liaison de valence ou un atome d'oxygène ou un atome de soufre, un groupe sulfinyle ou sulfonyle, un groupe CH2S ou un groupe NH, n est un nombre entier de 1 à 3, et R1 à R4, qui peuvent être identiques ou différents indépendamment l'un de l'autre, représentent chacun un atome d'hydrogène, un reste aliphatique de 1 à 6 atomes de carbone, ainsi que leurs tautomères, énantiomères, diastéréomères et leurs sels physiologiquement compatibles. En outre, l'invention concerne des médicaments renfermant des composés de formule (I), notamment pour le traitement d'infections virales.
EP92913494A 1991-07-05 1992-06-30 DERIVES DIBENZ b,e]AZEPINES ET MEDICAMENTS LES CONTENANT Withdrawn EP0593536A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4122240A DE4122240A1 (de) 1991-07-05 1991-07-05 Dibenz(b,e)azepinderivate und diese enthaltende arzneimittel
DE4122240 1991-07-05
PCT/EP1992/001465 WO1993001195A1 (fr) 1991-07-05 1992-06-30 DERIVES DIBENZ[b,e]AZEPINES ET MEDICAMENTS LES CONTENANT

Publications (1)

Publication Number Publication Date
EP0593536A1 true EP0593536A1 (fr) 1994-04-27

Family

ID=6435479

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92913494A Withdrawn EP0593536A1 (fr) 1991-07-05 1992-06-30 DERIVES DIBENZ b,e]AZEPINES ET MEDICAMENTS LES CONTENANT

Country Status (6)

Country Link
EP (1) EP0593536A1 (fr)
JP (1) JPH06508840A (fr)
AU (1) AU2194292A (fr)
CA (1) CA2111710A1 (fr)
DE (1) DE4122240A1 (fr)
WO (1) WO1993001195A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
MX2011005242A (es) 2008-11-28 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos.
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (fr) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2
JP5852664B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
ME03518B (fr) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation
WO2015110435A1 (fr) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024040C (fr) * 1989-08-29 2002-02-19 Karl D. Hargrave Dibenz[b,f][1,4]oxazepine (et thiazepine)-11 (10h)-ones et-thiones et leur utilisation pour la prevention et le traitement du sida

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9301195A1 *

Also Published As

Publication number Publication date
WO1993001195A1 (fr) 1993-01-21
AU2194292A (en) 1993-02-11
CA2111710A1 (fr) 1993-01-21
DE4122240A1 (de) 1993-01-07
JPH06508840A (ja) 1994-10-06

Similar Documents

Publication Publication Date Title
EP0026317B1 (fr) 1,4-Dihydropyridines optiquement actifs, procédés pour leur préparation et leur utilisation comme médicaments
EP0008391B1 (fr) Benzimidazoles, leur préparation et médicaments les contenant
DE69412322T2 (de) Xanthin-Derivate
EP0593536A1 (fr) DERIVES DIBENZ b,e]AZEPINES ET MEDICAMENTS LES CONTENANT
EP0496753A1 (fr) 2-bicyclo-benzimidazoles, procede pour leur fabrication et medicaments les contenant
DE3851114T2 (de) Trizyklische Verbindungen.
EP0114270B1 (fr) Dérivés acyliques de dianhydro-1,4:3,6 hexitols, procédé pour leur préparation et leur application comme médicaments
DE2940833C2 (fr)
EP0569457B1 (fr) Utilisation de derives de thiazolo-[2,3-a]isoindol en tant que medicaments anti-viraux et nouveaux derives de thiazolo- [2,3-a]isoindol
EP0556245B1 (fr) Utilisation de derives de la thiazoloisoindolinone comme medicaments antiviraux
DE3532279A1 (de) 1,4-benzoxathiin-derivate
EP0697405A1 (fr) Dérivés de quinoléines substituées, procédé pour leur préparation et leur utilisation
WO1993005047A1 (fr) Nouveaux derives tricycliques de thiazole et d'oxazole a action antivirale
EP0665228A1 (fr) Compositions pharmaceutiques contenant 3-phenylsulfonyl-3,7-diazabicyclo 3,3,1 nonanes
DE69219801T2 (de) 9-Aminotetrahydroakridinederivate und verwandte Derivate, Verfahren zur ihrer Herstellung und ihre Anwendung als Arzneimittel
WO1992015310A1 (fr) Utilisation d'iso-indolinones tricycliques comme medicaments antiviraux, et nouvelles iso-indolinones optiquement actives
EP0213295B1 (fr) Dérivés de thiéno-1,2-thiazole, leur procédé de préparation et compositions pharmaceutiques les contenant
EP0180833B1 (fr) Dérivés de la 4-oxopyrido[2,3-d]pyrimidine, procédé pour leur préparation et médicaments les contenant
EP0085893B1 (fr) Pyridobenzodiazépinones, procédé pour leur préparation et compositions pharmaceutiques les contenant
EP0158956A2 (fr) 4-(Nitrophényl)-tétrahydropyridines, leur procédé de préparation et leur application comme médicaments
EP0086981B1 (fr) Thienobenzodiazépinones substituées, procédé pour leur préparation et médicaments contenant ces composés
EP0559815B1 (fr) Derives optiquement actifs de thiazolo-isoindolinone a effet antiviral
EP0640088B1 (fr) Nouveaux derives thiazoliques et thiaziniques tricycliques, et medicaments antiviraux contenant ces derives
DE2310746A1 (de) Verfahren zur herstellung von neuen 1,4-dihydrochinolinen sowie ihre verwendung als arzneimittel
DE1695212B2 (de) Verfahren zur Herstellung von Iodininderivaten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931204

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19980316

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROCHE DIAGNOSTICS GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990724

RTI1 Title (correction)

Free format text: DIBENZ B,E AZEPINE DERIVATIVES AND DRUGS CONTAINING THEM